Last update 15 May 2025

REGN9933

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
REGN 9933, REGN-9933
Target
Action
inhibitors
Mechanism
F11 inhibitors(Coagulation factor XI inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ThrombosisPhase 2
Belgium
24 May 2023
ThrombosisPhase 2
Bulgaria
24 May 2023
ThrombosisPhase 2
Canada
24 May 2023
ThrombosisPhase 2
Hungary
24 May 2023
ThrombosisPhase 2
Latvia
24 May 2023
ThrombosisPhase 2
Lithuania
24 May 2023
ThrombosisPhase 2
Poland
24 May 2023
Venous ThromboembolismPhase 2
Belgium
24 May 2023
Venous ThromboembolismPhase 2
Bulgaria
24 May 2023
Venous ThromboembolismPhase 2
Canada
24 May 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
560
gfnfjitbdp(snxrgzntdd) = eznezuyjrj vrfrjddqjh (lnkuuvalbz )
Positive
19 Dec 2024
gfnfjitbdp(snxrgzntdd) = bllfghhlxh vrfrjddqjh (lnkuuvalbz )
Phase 1
-
56
REGN9933 IV 3-300 mg
kenbsqfshw(njurkflral) = psvqcrwmhg hvwuvwdngs (rgdjwxaqyq )
Positive
31 Aug 2024
REGN9933 SC 100 mg & 300 mg
kenbsqfshw(njurkflral) = krmlwifdep hvwuvwdngs (rgdjwxaqyq )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free